Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Open in API
Filings indexed 1,245 across all filing types
Latest filing 2022-05-30 AGM Information
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
Newspaper Advertisements
AGM Information Classification · 95% confidence The document contains a newspaper advertisement notice related to the 37th Annual General Meeting (AGM) of Bliss GVS Pharma Ltd., scheduled for June 28, 2022. It references compliance with SEBI and MCA circulars regarding the AGM. The document also includes an auction notice from Fedbank Financial Services Ltd. and a statement of audited financial results for Fino Finance Private Limited for the quarter and year ended March 31, 2022. However, the primary focus and the first part of the document is the AGM advertisement notice. The document is about the announcement of the AGM and related public notice, not the AGM presentation materials themselves. Therefore, it fits best under AGM Information (AGM-R) as it is a notice/advertisement related to the AGM. The length of the document (15,000 characters) supports it being more than a brief announcement but still primarily an AGM-related notice rather than a full annual report or financial statement filing. Confidence is high due to clear references to the AGM notice and regulatory compliance for AGM disclosures.
2022-05-30 English
Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copy of advertisement of public ....
AGM Information Classification · 95% confidence The document contains a newspaper advertisement notice regarding the 37th Annual General Meeting (AGM) of Bliss GVS Pharma Ltd., scheduled for June 28, 2022. It references compliance with SEBI and MCA circulars related to the AGM. The content is primarily an announcement of the AGM and related public notice, not the AGM materials or minutes themselves. Additionally, the document includes an auction notice from Fedbank Financial Services Ltd. and a statement of audited financial results for Fino Finance Private Limited for the quarter and year ended March 31, 2022. However, the financial results appear as a summary table and not a full detailed report. The main focus and majority content is the AGM public notice advertisement. According to the classification rules, announcements and notices related to the AGM fall under AGM Information (AGM-R). The document length is sufficient and contains actual text of the advertisement, not just a brief mention or link, so it is not a Report Publication Announcement (RPA). Therefore, the best fitting classification is AGM Information (AGM-R).
2022-05-30 English
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shruti Vishal Rao & PACs
Major Shareholding Notification Classification · 100% confidence The document is a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. It details the acquisition of shares by a promoter of the company, including specifics about the number of shares acquired and the percentage of shareholding before and after the acquisition. The document is addressed to stock exchanges and is a formal notification of a change in substantial shareholding. This fits the definition of a Major Shareholding Notification (MRQ), which involves notification of changes in significant share ownership levels crossing thresholds.
2022-05-27 English
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shruti Vishal Rao & PACs
Major Shareholding Notification Classification · 100% confidence The document is a disclosure pursuant to Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. It details the acquisition of shares by an acquirer in Bliss GVS Pharma Limited, including the number of shares acquired, percentage of shareholding before and after acquisition, mode of acquisition, and dates. This type of document is a notification of a change in significant share ownership levels, which fits the definition of a Major Shareholding Notification (MRQ). The document is not a full report but a regulatory disclosure of share acquisition.
2022-05-27 English
General updates
Regulatory Filings Classification · 95% confidence The document is titled 'Annual Secretarial Compliance Report for the year ended March 31, 2022' and is addressed to stock exchanges (NSE and BSE). It references compliance with SEBI regulations and details examination of filings, records, and compliance with various SEBI regulations during the review period. The document includes observations on compliance, deviations, and actions taken by regulatory bodies. It is a compliance report related to secretarial and regulatory adherence rather than a financial report or earnings release. It is not an announcement of a report but the report itself, containing substantive compliance information. This fits the category of Regulatory Filings (RNS) as it is a regulatory compliance report and does not fall under other specific categories like Annual Report, Audit Report, or Management Reports.
2022-05-26 English
Pursuant to Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular no. CIR/CFD/CMD1/27/2019 dated 8th February, 2019, please ....
Regulatory Filings Classification · 95% confidence The document is titled 'Annual Secretarial Compliance Report for the year ended March 31, 2022' and is addressed to stock exchanges. It references compliance with SEBI regulations and details examination of company filings and governance compliance for the financial year ended March 31, 2022. The content focuses on regulatory compliance, board composition, and actions taken by regulatory bodies. It is a compliance report rather than a financial report or earnings release. It does not contain financial statements or management discussion of financial results. It is not an announcement of a report but the report itself. This type of document is best classified under Regulatory Filings (RNS) as it is a regulatory compliance report that does not fit other specific categories like Annual Report or Management Reports.
2022-05-26 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.